Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 trial)

被引：102

作者：

Januzzi, JL

Cannon, CP

DiBattiste, PM

Murphy, S

Weintraub, W

Braunwald, E

机构：

[1] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA

[2] Merck Res Labs, West Point, PA USA

[3] Emory Univ, Atlanta, GA 30322 USA

[4] Brigham & Womens Hosp, Boston, MA 02115 USA

[5] TIMI Study Grp, Boston, MA USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2002年 / 90卷 / 11期

关键词：

D O I：

10.1016/S0002-9149(02)02844-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Among patients in the Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS)-Thrombolysis In Myocardial Infarction (TIMI) 18 study, decreasing renal function was associated with an increased prevalence of high-risk clinical findings, more extensive coronary artery disease, and independently associated with a high rate of adverse ischemic events after non-ST-segment elevation acute coronary syndrome (NSTE ACS). Across the range of renal function among patients in TACTICS-TIMI 18, the use of tirofiban plus an early invasive strategy was superior to conservative, ischemia-guided NSTE ACS management.

引用

收藏

页码：1246 / +

页数：5

相关论文

共 13 条

[1] Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery [J].

Anderson, RJ ;

O'Brien, M ;

MaWhinney, S ;

VillaNueva, CB ;

Moritz, TE ;

Sethi, GK ;

Henderson, WG ;

Hammermeister, KE ;

Grover, FL ;

Shroyer, AL .

KIDNEY INTERNATIONAL, 1999, 55 (03) :1057-1062

[2]

Asinger R W, 2001, J Invasive Cardiol, V13, P21

[3]

Bazzino O, 1998, NEW ENGL J MED, V338, P1488

[4] Clinical predictors of in-hospital prognosis in unstable angina:: ECLA 3 [J].

Bazzino, O ;

Díaz, R ;

Tajer, C ;

Paviotti, C ;

Mele, E ;

Trivi, M ;

Piombo, A ;

Prado, AH ;

Paolasso, E .

AMERICAN HEART JOURNAL, 1999, 137 (02) :322-331

[5] The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions [J].

Best, PJM ;

Lennon, R ;

Ting, HH ;

Bell, MR ;

Rihal, CS ;

Holmes, DR ;

Berger, PB .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (07) :1113-1119

[6] Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. [J].

Cannon, CP ;

Weintraub, WS ;

Demopoulos, LA ;

Vicari, R ;

Frey, MJ ;

Lakkis, N ;

Neumann, FJ ;

Robertson, DH ;

DeLucca, PT ;

DiBattiste, PM ;

Gibson, CM ;

Braunwald, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1879-1887

[7] Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency - Results from the platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) trial [J].

Januzzi, JL ;

Snapinn, SM ;

DiBattiste, PM ;

Jang, IK ;

Theroux, P .

CIRCULATION, 2002, 105 (20) :2361-2366

[8]

Luft FC, 2000, BASIC RES CARDIOL, V95, P72

[9] Effectiveness of and adverse events after percutaneous coronary intervention in patients with mild verses severe renal failure [J].

Rubenstein, MH ;

Sheynberg, BV ;

Harrell, LC ;

Schunkert, H ;

Bazari, H ;

Palacios, IF .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (07) :856-860

[10]

Rubenstein MH, 2000, CIRCULATION, V102, P2966